The global Tamiflu (Oseltamivir Phosphate) market is booming, projected to reach US$ 2.7 billion by 2034, driven by increasing influenza cases, innovative formulations, and strategic collaborations. Generic availability is also boosting accessibility, particularly in developing regions.
The flu can be a real drag, especially for those with compromised immune systems and young children. This article explores the science behind flu transmission, shedding light on how long someone can be contagious and why it’s crucial to understand the virus’s tricks. Discover the key factors that influence contagiousness, including the role of the flu vaccine and the latest research on preventing the spread of influenza.
New data from the CDC reveals that the 2024 flu shot significantly reduced the risk of flu-related hospitalizations by 35% in high-risk individuals, including young children, older adults, and those with chronic health conditions. The findings, based on data from five South American countries, offer promising insight into the potential effectiveness of the upcoming Northern Hemisphere flu season.
GlaxoSmithKline (GSK) has announced positive results from a Phase 2 trial for its mRNA seasonal influenza vaccine program. The trial showed strong immune responses against influenza A and B strains in both older and younger adults, paving the way for further development.
Respiratory viruses, such as influenza and SARS-CoV-2, pose a significant threat to global health. Despite advancements in vaccines and therapies, these viruses remain a major public health concern. A recent study investigated the potential of intranasal neomycin administration to induce antiviral protection in murine models. The findings revealed that intranasal neomycin evoked robust expression of interferon-stimulated genes (ISGs) in the upper respiratory tract, providing protection against both influenza A virus and SARS-CoV-2. This protection was independent of the host microbiome or interferon-related pathways. The study highlights the therapeutic and prophylactic potential of neomycin against respiratory viruses.
As of April 7-13, COVID-19 activity remained moderate, with two deaths recorded among seniors. Hospitalizations increased slightly to 18, including two aged 45-64. Influenza activity decreased, but five people, including a child under four and two youths, were hospitalized. No flu deaths were reported, and there were 74 lab-confirmed influenza cases. Spring COVID-19 vaccine boosters are available for high-risk individuals until June 15.
According to a recent survey, a majority of experts believe that the next pandemic is likely to be caused by a flu virus strain. This concern stems from the long-term research on influenza, which shows that while seasonal outbreaks are typically controlled, a new strain with increased virulence could lead to a global outbreak. The flu virus is a highly contagious respiratory infection that can cause severe symptoms, especially in vulnerable populations such as the elderly and those with underlying health conditions. Vaccination remains the most effective way to curb its spread, and experts emphasize the importance of personal hygiene practices to minimize the risk of transmission. Additionally, scientists are also monitoring the potential for avian influenza virus (H5N1) to evolve and pose a threat to humans.
According to a recent study, the most likely cause of the next pandemic is a type of flu virus. This is supported by the findings of a survey conducted among infectious disease experts worldwide, with 57% of them ranking influenza as the primary threat. Experts also identified Disease X, SARS-CoV-2, SARS-CoV, and Ebola viruses as other potential pandemic triggers.
